To conclude, we show how liver fibrosis in preclinical models differentially correlates with TGFBi and POSTN levels in response to deficiency for Stab1 or Stab2, bearing consequences for potential anti-Stabilin therapies. This evidence concerns the gene TGFBI and Hepatic fibrosis.